Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

Running, not enrolling · Not applicable

Conditions studied: Aortic Valve Stenosis

In brief

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR. The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial protocol is to conclude the randomized phase of the trial and initiate the single-arm, non-randomized, continued access phase of the trial.

Key facts

Study ID

NCT02701283

Run by

Medtronic Cardiovascular

People needed

2223

Starts

2016-03-01

Expected to finish

2029-06-01

Last updated by the study team

2026-05-07

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Severe aortic stenosis, defined as follows:
• For symptomatic patients:
• Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean gradient ≥40 mmHg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest
• For asymptomatic patients:
• Very severe aortic stenosis with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec , or mean gradient ≥60 mmHg by transthoracic echocardiography at rest, OR
• Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean gradient ≥40 mmHg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR
• Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND a left ventricular ejection fraction <50%.
• Documented heart team agreement of low risk for SAVR, where low risk is defined as predicted risk of mortality for SAVR <3% at 30 days per multidisciplinary local heart team assessment.
• The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

You may not qualify if…

• Any condition considered a contraindication for placement of a bioprosthetic valve (eg, subject is indicated for mechanical prosthetic valve).
• A known hypersensitivity or contraindication to any of the following that cannot be adequately pre-medicated:
• aspirin or heparin (HIT/HITTS) and bivalirudin
• ticlopidine and clopidogrel
• Nitinol (titanium or nickel)
• contrast media
• Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states.
• Ongoing sepsis, including active endocarditis.
• Any percutaneous coronary or peripheral interventional procedure with a bare metal stent within 30 days prior to randomization, or drug eluting stent performed within 180 days prior to randomization.
• Multivessel coronary artery disease with a Syntax score >22 and/or unprotected left main coronary artery.
• Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 10 weeks of Heart Team assessment.
• Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
• Recent (within 2 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
• Gastrointestinal (GI) bleeding that would preclude anticoagulation.
• Subject refuses a blood transfusion.
• Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
• Estimated life expectancy of less than 24 months due to associated non-cardiac co-morbid conditions.
• Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams.
• Currently participating in an investigational drug or another device trial (excluding registries).
• Evidence of an acute myocardial infarction ≤30 days before the trial procedure due to unstable coronary artery disease (WHO criteria).
• Need for emergency surgery for any reason.
• Subject is pregnant or breast feeding.
• Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable
• Pre-existing prosthetic heart valve in any position.
• Severe mitral regurgitation amenable to surgical replacement or repair.

Where it is running

• Scripps Memorial Hospital La Jolla — La Jolla, California, United States
• University of Southern California University Hospital — Los Angeles, California, United States
• El Camino Hospital — Mountain View, California, United States
• Mercy General Hospital — Sacramento, California, United States
• Los Robles Hospital & Medical Center — Thousand Oaks, California, United States
• University of Colorado Hospital — Aurora, Colorado, United States
• Yale New Haven Hospital — New Haven, Connecticut, United States
• Morton Plant Hospital — Clearwater, Florida, United States
• Delray Medical Center — Delray Beach, Florida, United States
• HealthPark Medical Center — Fort Myers, Florida, United States
• University of Miami Hospital — Miami, Florida, United States
• Tallahassee Research Institute, Inc. — Tallahassee, Florida, United States
• Piedmont Atlanta Hospital — Atlanta, Georgia, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Saint Vincent Heart Center of Indiana — Indianapolis, Indiana, United States
• Mercy Medical Center — Des Moines, Iowa, United States
• The University of Kansas Hospital — Kansas City, Kansas, United States
• Jewish Hospital — Louisville, Kentucky, United States
• Terrebonne General Medical Center — Houma, Louisiana, United States
• University of Maryland Medical Center — Baltimore, Maryland, United States
• MedStar Union Memorial Hospital — Baltimore, Maryland, United States
• The Johns Hopkins Hospital — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Abrazo Arizona Heart Hospital — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.